title: Intravitreal bevacizumab in postoperative pseudophakic cystoid macular edema: does it really work?
authors.forename: Martin S
authors.initials: MS
authors.lastname: Spitzer
authors.forename: Peter
authors.initials: P
authors.lastname: Szurman
authors.forename: Karl U
authors.initials: KU
authors.lastname: Bartz-Schmidt
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002387:Cataract Extraction; D005240:Feasibility Studies; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D010865:Pilot Projects; D011183:Postoperative Complications; D019591:Pseudophakia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D019233:Retreatment; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab